ClinicalTrials.gg
Not yet recruitingNCT07329543Updated Jan 9, 2026

AGE Burden and Response to Antiresorptive Therapy in Osteoporosis

An observational study in Osteoporosis and Postmenopausal Osteoporosis, sponsored by Bursa City Hospital. Not yet recruiting. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.

Primary conditionOsteoporosis, PostmenopausalRegistry: OsteoporosisReclassifiedWhy we changed it
Registry
Osteoporosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoporosis, Postmenopausal
Why
  1. The study's listed conditions name Osteoporosis, Postmenopausal, a narrower term within Osteoporosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bursa City Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
50 Years and older
Sex
All
01

Study summary

Osteoporosis is a common condition that increases the risk of bone fractures. Although antiresorptive treatments such as bisphosphonates and denosumab are effective in increasing bone mineral density, some patients continue to experience fractures despite treatment.

Advanced glycation end-products (AGEs) accumulate in the body over time and can negatively affect bone quality by altering collagen structure and increasing inflammation. The role of AGE burden in predicting response to osteoporosis treatment has not been fully established.

This prospective cohort study aims to evaluate whether baseline AGE burden, measured non-invasively using skin autofluorescence, is associated with treatment response in patients receiving antiresorptive therapy for osteoporosis. Changes in bone mineral density, bone turnover markers, and fracture outcomes will be analyzed in relation to baseline AGE levels. The results of this study may help identify patients at risk for reduced treatment response and residual fracture risk.

02

Conditions studied

  • Osteoporosis
  • Postmenopausal Osteoporosis

Browse trials for

03

In context

Osteoporosis, Postmenopausal Reclassified

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

This study's planned enrollment of 240 is above the median of 160 across 57 observational studies indexed under Osteoporosis, Postmenopausal.

Browse Osteoporosis, Postmenopausal studies →

Lead sponsor

Bursa City Hospital is the lead sponsor of 71 studies on the registry; 31 are open to participants now.

Compared within Osteoporosis, Postmenopausal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoporosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adults aged 50 years and older with a diagnosis of osteoporosis who are initiating antiresorptive therapy as part of routine clinical care. Participants will receive either denosumab or bisphosphonate treatment according to standard clinical indications. The study will prospectively evaluate the association between baseline advanced glycation end-product (AGE) burden and treatment response, including changes in bone mineral density, bone turnover markers, and fracture outcomes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 50 years
  • Diagnosis of osteoporosis based on dual-energy X-ray absorptiometry (DXA) criteria (T-score ≤ -2.5 at the lumbar spine, total hip, or femoral neck) or presence of a prior fragility fracture
  • Planned initiation of antiresorptive therapy (denosumab or bisphosphonate) as part of routine clinical care
  • Ability to undergo DXA measurements at baseline and during follow-up
  • Ability and willingness to provide written

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of diabetes mellitus (type 1 or type 2)
  • Chronic kidney disease with estimated (eGFR) \< 60 mL/min/1.73 m²
  • Active or history of malignancy within the past 5 years
  • Secondary causes of osteoporosis (including hyperparathyroidism, hyperthyroidism, Cushing's syndrome, malabsorption syndromes, or chronic liver disease)
  • Use of medications known to significantly affect bone metabolism other than antiresorptive therapy (e.g., long-term systemic , anabolic osteoporosis agents)
  • Prior treatment with denosumab or bisphosphonates within the last 12 months
  • Inflammatory rheumatic diseases or chronic inflammatory conditions that may affect bone metabolism
  • Pregnancy or breastfeeding
  • Inability to comply with study procedures or follow-up visits
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No

Groups and cohorts

  • Denosumab Group

    Patients with osteoporosis receiving denosumab as part of routine clinical care.

  • Bisphosphonate Group

    Patients with osteoporosis receiving bisphosphonate therapy as part of routine clinical care.

06

What researchers measure

Primary outcomes

  1. Percentage Change in Total Hip Bone Mineral Density

    Percentage change in total hip bone mineral density (BMD) from baseline to 12 months, measured by dual-energy X-ray absorptiometry (DXA), in relation to baseline advanced glycation end-product (AGE) burden.

    Time frame: Baseline to 12 months

Secondary outcomes

  1. Percentage Change in Lumbar Spine Bone Mineral Density (L1-L4)

    Percentage change in lumbar spine (L1-L4) bone mineral density from baseline to 12 months measured by DXA.

    Time frame: Baseline to 12 months

  2. Serum Concentration of Bone Turnover Markers (CTX and P1NP)

    Changes in bone turnover markers, including serum C-terminal telopeptide of type I collagen (CTX) and procollagen type I N-terminal propeptide (P1NP), from baseline to 3 and 12 months.

    Time frame: Baseline to 3 months and 12 months

  3. Incident Fragility Fractures

    Occurrence of new fragility fractures during the follow-up period, assessed by patient report and medical records.

    Time frame: Up to 12 months

  4. Association Between Baseline AGE Burden and Treatment Response

    Association between baseline AGE burden measured by skin autofluorescence and changes in bone mineral density and bone turnover markers during antiresorptive therapy.

    Time frame: Baseline to 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Sanguineti R, Puddu A, Mach F, Montecucco F, Viviani GL. Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediators Inflamm. 2014;2014:975872. doi: 10.1155/2014/975872. Epub 2014 Mar 20. PubMed 24771986 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jan 2027, 12 months later.

Of 23 observational studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 65. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2025
First posted
Jan 9, 2026
StartEst.
Jan 15, 2026
Primary completionEst.
Jan 15, 2027
CompletionEst.
Apr 15, 2027
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07329543
Lead sponsor
Bursa City Hospital
Responsible party
Taner Dandinoğlu (Principal Investigator, Bursa City Hospital) — Principal investigator
First posted
Jan 9, 2026
Start date
Jan 15, 2026 (estimated)
Primary completion
Jan 15, 2027 (estimated)
Completion
Apr 15, 2027 (estimated)
Last update
Jan 9, 2026

Study contacts

Taner Dandinoğlu, MD
Contact
dandinoglu@gmail.com
+905336914077

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion